Tesamorelin
Also known as Egrifta, TH9507
Tesamorelin is a stabilized synthetic analog of growth hormone releasing hormone (GHRH) that is FDA-approved (as Egrifta) for reducing excess visceral adipose tissue in HIV-associated lipodystrophy. It has one of the strongest clinical trial evidence bases among GHRH-class peptides, with multiple randomized controlled trials supporting reductions in visceral fat and increases in IGF-1. Outside its approved indication, it has drawn research and community interest for body composition support more broadly, though this use is off-label and less directly supported by trial data. Ongoing monitoring of blood glucose and IGF-1 is commonly recommended during use.
Reported benefits
- Clinically demonstrated reduction in visceral adipose tissue
- Increases IGF-1
- Improves body composition in studied populations
- Strong randomized-trial evidence base
How it works
Tesamorelin carries a trans-3-hexenoic acid addition to the N-terminus of GHRH(1-44) that confers resistance to degradation by the enzyme DPP-4, extending its activity compared to unmodified GHRH. It binds pituitary GHRH receptors to increase pulsatile GH secretion and downstream IGF-1, which in clinical trials was associated with measurable reductions in visceral fat mass.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 1 mg | once daily |
| Moderate | 2 mg | once daily |
| High | 3 mg | once daily |
Estimate your dose
Dose estimator
Educational estimate for Tesamorelin, scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for Tesamorelin. Educational only.
Draw to this mark
40units
= 0.4 mL for a 2 mg dose
Concentration
5 mg/mL
Doses per vial
5
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Primarily used as a standalone agent within its approved indication; combination with GHRPs is described anecdotally rather than in clinical trials.
Common protocols
Common questions
What is Tesamorelin used for?
Tesamorelin is a stabilized synthetic analog of growth hormone releasing hormone (GHRH) that is FDA-approved (as Egrifta) for reducing excess visceral adipose tissue in HIV-associated lipodystrophy. It has one of the strongest clinical trial evidence bases among GHRH-class peptides, with multiple randomized controlled trials supporting reductions in visceral fat and increases in IGF-1. Outside its approved indication, it has drawn research and community interest for body composition support more broadly, though this use is off-label and less directly supported by trial data. Ongoing monitoring of blood glucose and IGF-1 is commonly recommended during use. Reported benefits include clinically demonstrated reduction in visceral adipose tissue, increases igf-1, improves body composition in studied populations.
What is a typical Tesamorelin dose?
Reported ranges run 1-3 mg. A low protocol is 1 mg once daily, and a high protocol is 3 mg once daily. This is reference information, not a dosing recommendation.
What is the half life of Tesamorelin?
~26-38 min. That is what sets the dosing frequency, and it is why the timing guidance is ~30 min before bed, empty stomach.
How is Tesamorelin administered?
Subcutaneous: into fat, under the skin. Injected subcutaneously into the abdomen, per the approved dosing regimen
How long is a Tesamorelin cycle?
12 weeks on, followed by 4 weeks off. The FDA-labeled Egrifta regimen is continuous daily dosing under physician supervision, without scheduled on/off cycling
What are the side effects of Tesamorelin?
Reported side effects include injection-site reactions, joint pain (arthralgia), peripheral edema, elevated blood glucose, muscle pain (myalgia). Evidence level for this compound is well studied.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. Tesamorelin may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →